Animal, Inc. is a focused enterprise supporting the
development of its flagship device for a single indication
(labeling self antibodies with an imaging tag). Our
leading clinical target is for the detection and treatment of
a variety of cancer tissues in companion animals.
device is also an effective platform technology. It can
be utilized in an out-patient or clinic setting and treatment
can be administered by trained technicians or nursing staff.
will be generated through sale of the device for veterinary
use, with an annual North American market in the $10M - $150M
range. We will also secure
licenses with biotech and pharmaceutical companies interested
in developing the technology for humans.
Please contact us if you would like to
learn more about investing in this technology, or in
collaborating with us on your project.
Gary McNeil, V.P. R&D at